EUR 8.7
(0.0%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 7.1 Million EUR | 47.92% |
2022 | 4.8 Million EUR | -48.39% |
2021 | 9.3 Million EUR | -88.45% |
2020 | 80.5 Million EUR | -13.16% |
2019 | 92.7 Million EUR | -1.38% |
2018 | 94 Million EUR | 8.55% |
2017 | 86.6 Million EUR | -8.65% |
2016 | 94.8 Million EUR | 61.22% |
2015 | 58.8 Million EUR | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q2 | 10.2 Million EUR | 0.0% |
2024 Q1 | 10.2 Million EUR | 43.66% |
2023 Q1 | 900 Thousand EUR | -81.25% |
2023 FY | 7.1 Million EUR | 47.92% |
2023 Q3 | 1 Million EUR | -82.14% |
2023 Q4 | 7.1 Million EUR | 610.0% |
2023 Q2 | 5.6 Million EUR | 522.22% |
2022 Q4 | 4.8 Million EUR | 700.0% |
2022 Q2 | 5.5 Million EUR | 205.56% |
2022 FY | 4.8 Million EUR | -48.39% |
2022 Q1 | 1.8 Million EUR | -80.65% |
2022 Q3 | 600 Thousand EUR | -89.09% |
2021 Q4 | 9.3 Million EUR | 257.69% |
2021 FY | 9.3 Million EUR | -88.45% |
2021 Q3 | 2.6 Million EUR | -93.16% |
2021 Q2 | 38 Million EUR | 26.67% |
2021 Q1 | 30 Million EUR | -62.73% |
2020 Q2 | 94.5 Million EUR | 0.0% |
2020 Q4 | 80.5 Million EUR | 0.0% |
2020 FY | 80.5 Million EUR | -13.16% |
2020 Q3 | 80.5 Million EUR | -14.81% |
2020 Q1 | 94.5 Million EUR | 1.94% |
2019 Q4 | 92.7 Million EUR | 0.0% |
2019 FY | 92.7 Million EUR | -1.38% |
2019 Q3 | 92.7 Million EUR | 0.76% |
2019 Q2 | 92 Million EUR | 0.0% |
2019 Q1 | 92 Million EUR | -2.13% |
2018 Q2 | 84.4 Million EUR | 0.0% |
2018 Q4 | 94 Million EUR | 0.0% |
2018 FY | 94 Million EUR | 8.55% |
2018 Q1 | 84.4 Million EUR | -2.54% |
2018 Q3 | 94 Million EUR | 11.37% |
2017 Q2 | 88.9 Million EUR | 0.0% |
2017 FY | 86.6 Million EUR | -8.65% |
2017 Q3 | 86.6 Million EUR | -2.59% |
2017 Q4 | 86.6 Million EUR | 0.0% |
2017 Q1 | 88.9 Million EUR | -6.22% |
2016 Q3 | 94.8 Million EUR | 84.8% |
2016 Q2 | 51.3 Million EUR | 0.0% |
2016 FY | 94.8 Million EUR | 61.22% |
2016 Q1 | 51.3 Million EUR | -12.76% |
2016 Q4 | 94.8 Million EUR | 0.0% |
2015 Q2 | 50.6 Million EUR | 0.0% |
2015 FY | 58.8 Million EUR | 0.0% |
2015 Q4 | 58.8 Million EUR | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
AB Science S.A. | 46.5 Million EUR | 84.734% |
Boiron SA | 198.7 Million EUR | 96.427% |
Fagron NV | 539.32 Million EUR | 98.684% |
Ipsen S.A. | 2.49 Billion EUR | 99.716% |
Vetoquinol SA | 165.12 Million EUR | 95.7% |